Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.40 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30593664 | 1.00 | ABCG2 (0.40) | ABCG2ASH1LKCNJ1KCNH2KDM1A | |
| SCHEMBL31194993 | 0.89 | ABCG2 (0.37) | ABCG2ASH1LKCNJ1KCNH2KDM1A | |
| SCHEMBL20971570 | 0.89 | ABCG2 (0.37) | ABCG2ASH1LKCNJ1KCNH2KDM1A | |
| SCHEMBL4106338 | 0.89 | KDM1A (0.40) | ABCG2ASH1LKCNJ1KCNH2KDM1A | |
| SCHEMBL19586454 | 0.82 | KDM1A (0.45) | ASH1LKDM1ABRD4DGAT2 | |
| SCHEMBL30593682 | 0.82 | KDM1A (0.45) | ASH1LKDM1ABRD4DGAT2 | |
| SCHEMBL1631169 | 0.80 | DYRK1A (0.43) | ABCG2ASH1LKCNJ1KCNH2KDM1A | |
| SCHEMBL28596296 | 0.79 | ALDH1A1 (0.47) | SIRT2ALDH1A1POLBLMNA | |
| SCHEMBL12996890 | 0.77 | ALDH1A1 (0.47) | SIRT2ALDH1A1POLBLMNA | |
| SCHEMBL30593659 | 0.74 | ASH1L (0.44) | ABCG2ASH1LKCNJ1KCNH2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245645-A1 | ASH1L INHIBITORS AND METHODS AND TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-25 | — | — | US | disclosed |
| US-11883381-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-01-30 | — | — | US | disclosed |
| CN-109414596-B | ASH1L inhibitors and methods of treatment therewith | 密歇根大学董事会 | 2023-09-29 | — | — | CN | disclosed |
| EP-3454945-B1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | UNIV MICHIGAN REGENTS (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20190142799-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-16 | — | — | US | disclosed |
| EP-3454945-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | The Regents Of The University Of Michigan (US) | 2019-03-20 | — | — | EP | disclosed |
| CN-109414596-A | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | 密歇根大学董事会 | 2019-03-01 | — | — | CN | disclosed |
| WO-2017197240-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017197240-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142799-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | ASH1L, DOT1L, CHD1L | ABCG2 3950/4885ASH1L 1/4885KCNJ1 4109/4885 |
| US-20240245645-A1 | ASH1L INHIBITORS AND METHODS AND TREATMENT THEREWITH | ASH1L, DOT1L, CHD1L | ABCG2 3972/4885ASH1L 1/4885KCNJ1 4198/4885 |
| US-11883381-B2 | ASH1L inhibitors and methods of treatment therewith | ASH1L, DOT1L, CHD1L | ABCG2 3950/4885ASH1L 1/4885KCNJ1 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.